{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T14:13:54Z","timestamp":1766067234499},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"22","license":[{"start":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:00:00Z","timestamp":1604016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Infusion of cytotoxic drugs carries the risk of occupational exposure of healthcare workers. Since disconnecting an infusion line is a source of contamination, flushing of tubing after infusion of cytotoxic agents is recommended, but the optimal volume of rinsing solution is unknown. The objective of this study was to assess whether postinfusion line flushing completely eliminates cytotoxics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Infusions were simulated with 3 cytotoxics (gemcitabine, cytarabine, and paclitaxel) diluted in 5% dextrose injection or 0.9% sodium chloride injection in 250-mL infusion bags. Infusion lines were flushed using 5% dextrose injection or 0.9% sodium chloride solution at 2 different flow rates. The remaining concentration of cytotoxics in the infusion line was measured by a validated high-performance liquid chromatography (HPLC) method after passage of every 10 mL of flushing volume until a total of 100 mL had been flushed through.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>All cytotoxics remained detectable even after line flushing with 80 mL of flushing solution (a volume 3-fold greater than the dead space volume within the infusion set). Gemcitabine and cytarabine were still quantifiable via HPLC even after flushing with 100 mL of solution. Efficacy of flushing was influenced by the lipophilicity of drugs but not by either the flushing solvent used or the flushing flow rate. After 2-fold dead space volume flushing, the estimated amount of drug remaining in the infusion set was within 0.19% to 0.56% of the prescribed dose for all 3 cytotoxics evaluated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Complete elimination of cytotoxics from an infusion line is an unrealistic objective. Two-fold dead space volume flushing could be considered optimal in terms of administered dose but not from an environmental contamination point of view. Even when flushed, the infusion set should still be considered a source of cytotoxic contamination.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxaa357","type":"journal-article","created":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T09:01:19Z","timestamp":1604048479000},"page":"1866-1873","source":"Crossref","is-referenced-by-count":3,"title":["Assessment of efficacy of postinfusion tubing flushing in reducing risk of cytotoxic contamination"],"prefix":"10.1093","volume":"77","author":[{"given":"Pauline","family":"Claraz","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Institut Universitaire du Cancer (IUCT) Oncopole, Institut Claudius Regaud, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Riff","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Institut Universitaire du Cancer (IUCT) Oncopole, CHU de Toulouse, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Vert","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Institut Universitaire du Cancer (IUCT) Oncopole, CHU de Toulouse, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elina","family":"Wolff","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Institut Universitaire du Cancer (IUCT) Oncopole, Institut Claudius Regaud, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Perriat","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Institut Universitaire du Cancer (IUCT) Oncopole, CHU de Toulouse, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana\u00efs","family":"Grand","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Institut Universitaire du Cancer (IUCT) Oncopole, CHU de Toulouse, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yann","family":"Cretu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Institut Universitaire du Cancer (IUCT) Oncopole, CHU de Toulouse, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Hennebelle","sequence":"additional","affiliation":[{"name":"Risk Management Unit, Institut Universitaire du Cancer (IUCT) Oncopole, Institut Claudius Regaud, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marie","family":"Canonge","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Institut Universitaire du Cancer (IUCT) Oncopole, CHU de Toulouse, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florent","family":"Puisset","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Institut Universitaire du Cancer (IUCT) Oncopole, Institut Claudius Regaud, Toulouse, France, and Centre de Recherches en Canc\u00e9rologie de Toulouse (CRCT), Team 14, INSERM UMR1037, Universit\u00e9 de Toulouse, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,10,30]]},"reference":[{"issue":"1","key":"2020103005011232200_CIT0001","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13046-019-1094-2","article-title":"Clinical development of targeted and immune based anti-cancer therapies","volume":"38","author":"Seebacher","year":"2019","journal-title":"J Exp Clin Cancer Res."},{"issue":"3","key":"2020103005011232200_CIT0002","doi-asserted-by":"crossref","first-page":"42","DOI":"10.21037\/cco.2016.04.01","article-title":"Chemotherapy principles of managing stage IV breast cancer in the United States","volume":"5","author":"Hernandez-Aya","year":"2016","journal-title":"Chin Clin Oncol."},{"issue":"30","key":"2020103005011232200_CIT0003","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1200\/JCO.2017.74.6065","article-title":"Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"35","author":"Hanna","year":"2017","journal-title":"J Clin Oncol."},{"issue":"3","key":"2020103005011232200_CIT0004","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11523-019-00641-9","article-title":"Current systemic treatment landscape of advanced gynecologic malignancies","volume":"14","author":"Pan","year":"2019","journal-title":"Target Oncol."},{"key":"2020103005011232200_CIT0005","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.clml.2016.02.007","article-title":"Acute myeloid leukemia: past, present, and prospects for the future","volume":"16","author":"Short","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"2020103005011232200_CIT0006","volume-title":"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016","author":"Connor","year":"2016"},{"issue":"1","key":"2020103005011232200_CIT0007","first-page":"16","article-title":"Detection of contamination with antineoplastic agents in a hospital pharmacy department","volume":"14","author":"Sessink","year":"1992","journal-title":"Pharm Weekbl Sci."},{"issue":"7","key":"2020103005011232200_CIT0008","first-page":"619","article-title":"Environmental contamination with cytotoxic drugs in healthcare using positive air pressure isolators","volume":"49","author":"Crauste-Manciet","year":"2005","journal-title":"Ann Occup Hyg."},{"issue":"2","key":"2020103005011232200_CIT0009","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF00381477","article-title":"Occupational exposure to antineoplastic agents at several departments in a hospital. Environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers","volume":"64","author":"Sessink","year":"1992","journal-title":"Int Arch Occup Environ Health."},{"issue":"3","key":"2020103005011232200_CIT0010","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.clinthera.2014.01.016","article-title":"Administration of anticancer drugs: exposure in hospital nurses","volume":"36","author":"Rioufol","year":"2014","journal-title":"Clin Ther."},{"issue":"1","key":"2020103005011232200_CIT0011","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00420-002-0383-8","article-title":"Uptake of antineoplastic agents in pharmacy and hospital personnel. Part I: monitoring of urinary concentrations","volume":"76","author":"Pethran","year":"2003","journal-title":"Int Arch Occup Environ Health."},{"issue":"3","key":"2020103005011232200_CIT0012","first-page":"231","article-title":"A pooled analysis to study trends in exposure to antineoplastic drugs among nurses","volume":"51","author":"Fransman","year":"2007","journal-title":"Ann Occup Hyg."},{"key":"2020103005011232200_CIT0013","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1191\/1078155203jp102oa","article-title":"External contamination of vials containing cytotoxic agents supplied by pharmaceutical manufacturers","volume":"9","author":"Favier","year":"2003","journal-title":"J Oncol Pharm Pract."},{"key":"2020103005011232200_CIT0014","first-page":"331","article-title":"Vapour pressures, evaporation behaviour and airborne concentrations of hazardous drugs\u202f: implications for occupational safety","volume":"26","author":"Kiffmeyer","year":"2002","journal-title":"Pharm J."},{"key":"2020103005011232200_CIT0015","first-page":"1","article-title":"ISOPP standards of practice. Safe handling of cytotoxics","volume":"13","author":"International Society of Oncology Pharmacy Practicioners Standards Committee","year":"2007","journal-title":"J Oncol Pharm Pract."},{"issue":"7","key":"2020103005011232200_CIT0016","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s004200000164","article-title":"Long-term monitoring of sister chromatid exchanges and micronucleus frequencies in pharmacy personnel occupationally exposed to cytostatic drugs","volume":"73","author":"Pilger","year":"2000","journal-title":"Int Arch Occup Environ Health."},{"issue":"24","key":"2020103005011232200_CIT0017","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.2146\/ajhp180564","article-title":"ASHP guidelines on handling hazardous drugs","volume":"75","author":"Power","year":"2018","journal-title":"Am J Health-Syst Pharm."},{"key":"2020103005011232200_CIT0018","author":"United States Pharmacopeia","year":"2019"},{"issue":"1","key":"2020103005011232200_CIT0019","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00420-012-0742-z","article-title":"Evaluation of working practices and surface contamination with antineoplastic drugs in outpatient oncology health care settings","volume":"86","author":"Kopp","year":"2013","journal-title":"Int Arch Occup Environ Health."},{"issue":"4","key":"2020103005011232200_CIT0020","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/FTD.0b013e31825a4d9c","article-title":"Minimization of the preanalytical error in pharmacokinetic analyses and therapeutic drug monitoring: focus on IV drug administration","volume":"34","author":"Kontny","year":"2012","journal-title":"Ther Drug Monit."},{"issue":"2","key":"2020103005011232200_CIT0021","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/FTD.0000000000000254","article-title":"Potential impact of infusion technique on drug delivery","volume":"38","author":"Simon","year":"2016","journal-title":"Ther Drug Monit."},{"key":"2020103005011232200_CIT0022","author":"International Conference on Harmonisation"},{"issue":"7","key":"2020103005011232200_CIT0023","doi-asserted-by":"crossref","first-page":"e0159052","DOI":"10.1371\/journal.pone.0159052","article-title":"Effectiveness of a closed-system transfer device in reducing surface contamination in a new antineoplastic drug-compounding unit: a prospective, controlled, parallel study","volume":"11","author":"Simon","year":"2016","journal-title":"PLoS ONE."},{"issue":"3","key":"2020103005011232200_CIT0024","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1310\/hpj4803-204","article-title":"Reduction in surface contamination with cyclophosphamide in 30 US hospital pharmacies following implementation of a closed-system drug transfer device","volume":"48","author":"Sessink","year":"2013","journal-title":"Hosp Pharm."},{"issue":"9","key":"2020103005011232200_CIT0025","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/ajhp\/zxz033","article-title":"Patterns and characteristics associated with surface contamination of hazardous drugs in hospital pharmacies","volume":"76","author":"Salch","year":"2019","journal-title":"Am J Health-Syst Pharm."},{"issue":"3","key":"2020103005011232200_CIT0026","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00420-012-0769-1","article-title":"Effectiveness of cleaning of workplace cytotoxic surface","volume":"86","author":"L\u00ea","year":"2013","journal-title":"Int Arch Occup Environ Health."},{"issue":"6","key":"2020103005011232200_CIT0027","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3322\/canjclin.56.6.354","article-title":"Preventing occupational exposures to antineoplastic drugs in health care settings","volume":"56","author":"Connor","year":"2006","journal-title":"CA Cancer J Clin."},{"key":"2020103005011232200_CIT0028","first-page":"CD012860","article-title":"Closed-system drug-transfer devices plus safe handling of hazardous drugs versus safe handling alone for reducing exposure to infusional hazardous drugs in healthcare staff","volume":"3","author":"Gurusamy","year":"2018","journal-title":"Cochrane Database Syst Rev."},{"issue":"17","key":"2020103005011232200_CIT0029","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1093\/ajhp\/zxz137","article-title":"Criticisms of Cochrane Review on closed-system transfer devices remain valid","volume":"76","author":"McDiarmid","year":"2019","journal-title":"Am J Health-Syst Pharm."},{"key":"2020103005011232200_CIT0030","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/ajhp\/zxz136","article-title":"Validity of criticism of Cochrane review on closed-system drug-transfer devices","volume":"76","author":"Gurusamy","year":"2019","journal-title":"Am J Health-Syst Pharm."},{"issue":"4","key":"2020103005011232200_CIT0031","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2146\/ajhp160948","article-title":"Multicenter evaluation of a new closed system drug-transfer device in reducing surface contamination by antineoplastic hazardous drugs","volume":"75","author":"Bartel","year":"2018","journal-title":"Am J Health-Syst Pharm."},{"issue":"14","key":"2020103005011232200_CIT0032","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.12968\/bjon.2018.27.14.S4","article-title":"Non-flushing of IV administration sets: an under-recognised under-dosing risk","volume":"27","author":"Cooper","year":"2018","journal-title":"Br J Nurs."},{"issue":"2","key":"2020103005011232200_CIT0033","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/10408347.2017.1416283","article-title":"Characteristics, properties and analytical methods of paclitaxel: a review","volume":"48","author":"Alves","year":"2018","journal-title":"Crit Rev Anal Chem."},{"issue":"1","key":"2020103005011232200_CIT0034","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1021\/js950286j","article-title":"Binding of taxol to plastic and glass containers and protein under in vitro conditions","volume":"85","author":"Song","year":"1996","journal-title":"J Pharm Sci."},{"issue":"1","key":"2020103005011232200_CIT0035","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/193229680900300126","article-title":"The impact of insulin adsorption onto the infusion sets in the adult intensive care unit","volume":"3","author":"Jakobsson","year":"2009","journal-title":"J Diabetes Sci Technol."},{"issue":"1","key":"2020103005011232200_CIT0036","doi-asserted-by":"crossref","first-page":"75","DOI":"10.5301\/JVA.2011.8487","article-title":"Flushing of intravascular access devices (IVADs) - efficacy of pulsed and continuous infusions","volume":"13","author":"Guiffant","year":"2012","journal-title":"J Vasc Access."},{"key":"2020103005011232200_CIT0037","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.colsurfa.2016.07.086","article-title":"Cloud point thermodynamics of paclitaxel-loaded microemulsion in the presence of glucose and NaCl","volume":"507","author":"Wang","year":"2016","journal-title":"Colloids Surf A Physicochem Eng Asp."},{"issue":"1-2","key":"2020103005011232200_CIT0038","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijpharm.2017.05.040","article-title":"Evaluation of tacrolimus sorption to PVC- and non-PVC-based tubes in administration sets: pump method vs. drip method","volume":"528","author":"Jin","year":"2017","journal-title":"Int J Pharm."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/77\/22\/1866\/34055779\/zxaa357.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/77\/22\/1866\/34055779\/zxaa357.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T09:01:44Z","timestamp":1604048504000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/77\/22\/1866\/5943268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,30]]},"references-count":38,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2020,10,30]]},"published-print":{"date-parts":[[2020,10,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxaa357","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,11,15]]},"published":{"date-parts":[[2020,10,30]]}}}